Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Celularity (CELU) EBITDA Margin (2020 - 2025)

Celularity (CELU) has disclosed EBITDA Margin for 6 consecutive years, with 593.62% as the latest value for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 133894.0% year-over-year to 593.62%; the TTM value through Dec 2025 reached 345.43%, down 18800.0%, while the annual FY2025 figure was 345.43%, 23865.0% down from the prior year.
  • EBITDA Margin hit 593.62% in Q4 2025 for Celularity, down from 436.66% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1266.58% in Q2 2022 and bottomed at 2479.56% in Q3 2023.
  • Average EBITDA Margin over 5 years is 591.18%, with a median of 300.4% recorded in 2025.
  • Year-over-year, EBITDA Margin skyrocketed 316245bps in 2022 and then plummeted -290776bps in 2023.
  • Celularity's EBITDA Margin stood at 83.2% in 2021, then surged by 805bps to 586.27% in 2022, then tumbled by -90bps to 59.05% in 2023, then tumbled by -3373bps to 1932.56% in 2024, then surged by 69bps to 593.62% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 593.62%, 436.66%, and 427.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.